Our group previously developed an allogenic, human granulocyte macrophage-colony stimulating factor (GM-CSF)-secreting whole-cell pancreatic cancer vaccine (GVAX) to promote T-cell responses against a range of tumor-associated antigens4–7. The gene discussed is CSF2; the disease is familial pancreatic carcinoma.